News: Endo Health Solutions Inc (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

33.55USD
3:25pm EDT
Price Change (% chg)

$-0.49 (-1.44%)
Prev Close
$34.04
Open
$34.02
Day's High
$34.59
Day's Low
$33.54
Volume
291,378
Avg. Vol
682,260
52-wk High
$38.31
52-wk Low
$25.01

Search Stocks
Select another date:

Fri, May 10 2013

FDA allows generic forms of Endo Health's Opana ER painkiller

- The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain drugs to prevent their abuse.

Continue Reading

UPDATE 1-FDA allows generic forms of Endo Health's Opana ER painkiller

May 10 - The U.S. Food and Drug Administration on Friday denied Endo Health Solutions' petition to block generic forms of its widely abused prescription pain drug Opana ER, a surprise decision by an agency that has recently come down hard on pain drugs to prevent their abuse.

Panel divided over safety of Endo's testosterone drug

- An advisory panel to the U.S. Food and Drug Administration was sharply divided on Thursday over whether a drug made by Endo Health Solutions Inc can safely be prescribed for men with low testosterone.

UPDATE 1-US panel divided over safety of Endo's testosterone drug

April 18 - An advisory panel to the U.S. Food and Drug Administration was sharply divided on Thursday over whether a drug made by Endo Health Solutions Inc can safely be prescribed for men with low testosterone.

U.S. FDA panel deadlocked over Endo's testosterone drug

April 18 - An advisory panel to the U.S. Food and Drug Administration was deadlocked over whether the agency should approve Endo Health Solutions Inc's experimental drug to treat low testosterone in men.

FDA staff concerned about safety of Endo's testosterone injection

- Reviewers for the U.S. Food and Drug Administration said safety data on Endo Health Solutions Inc's twice-rejected testosterone injection Aveed was "concerning" and showed that the therapy was associated with severe and immediate post-injection adverse events.

UPDATE 2-FDA staff concerned about safety of Endo's testosterone injection

April 16 - Reviewers for the U.S. Food and Drug Administration said safety data on Endo Health Solutions Inc's twice-rejected testosterone injection Aveed was "concerning" and showed that the therapy was associated with severe and immediate post-injection adverse events.

FDA staff concerned about safety of Endo's testosterone injection

April 16 - Reviewers for the U.S. Food and Drug Administration said safety data on Endo Health Solutions Inc's testosterone injection Aveed was "concerning," and showed the therapy was associated with severe and immediate post-injection adverse events.

Exclusive: Endo Health in talks with potential buyers - sources

NEW YORK - Endo Health Solutions Inc has held talks in recent weeks with drugmakers potentially interested in buying the maker of pain relief medication, people familiar with the matter said on Wednesday.

Endo Health says to miss 2013 forecast, CEO retires

Dec 12 - Endo Health Solutions Inc said it does not expect to meet its revenue and earnings forecast for 2013, and that its Chief Executive David Holveck will retire next year.

Select another date:

Market Views

» More ENDP.OQ Market Views

Press Releases

Search Stocks